Novo Nordisk(US:NVO) Ge Long Hui A P P·2026-01-16 09:41Group 1 - Novo Nordisk (NVO.US) shares rose by 2.6% in pre-market trading on January 16 [1] - The company has made progress in the obesity treatment sector with the registration of NNC0487-0111, a weekly subcutaneous injection for obese patients, marking its first Phase III clinical trial [1] - NNC0487-0111 (Amycretin) is a long-acting GLP-1 and insulin receptor agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations [1] Group 2 - The closing price of Novo Nordisk on January 15 was $57.20, with a pre-market price of $58.58 on January 16 [2] - The stock's trading volume was 25.75 million shares, with a market capitalization of $253.65 billion [2] - The stock has a 52-week high of $91.225 and a low of $43.080, with a dividend yield of 3.20% [2]